Head of Japanese doctors union warns of risk if Games go ahead; Facebook changes policy ‘in light of ongoing investigations into the origin of Covid’
- Biden orders US intelligence to intensify efforts to study Covid’s origins
- German scientists say they can improve vaccines to prevent blood clots
- Taiwan accuses China of interfering with Covid vaccine deals
- Record pace of Melbourne outbreak blamed for Victoria lockdown
- UK Covid updates – live
Two Covid-19 vaccines from China’s Sinopharm showed more than 70% efficacy against symptomatic cases, but it remains unclear how much protection they provide against severe or asymptomatic cases, according to the first detailed result of a large late-stage study published to the public.
A vaccine developed by a Wuhan-based subsidiary of Sinopharm was 72.8% effective against symptomatic COVID-19 at least two weeks after second injection, based on interim results, the peer-reviewed study published in the Journal of the American Medical Association showed on Wednesday.
India is changing its approach to vaccines – announcing that it has scrapped local trials for “well-established” foreign coronavirus vaccines to fast-track imports.
The country has been inoculating its people with the AstraZeneca vaccine produced locally at the Serum Institute, Covaxin made by local firm Bharat Biotech, and has begun rolling out Russia’s Sputnik V.
